NCT05725252View on ClinicalTrials.gov

To Evaluate the Safety and the Pharmacokinetics of NVP-2203

PHASE1CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

May 28, 2023

Primary Completion Date

June 11, 2023

Study Completion Date

July 5, 2023

Conditions
Healthy Volunteers
Interventions
DRUG

NVP-2203

NVP-2203(Combination of NVP-2203-R1 and NVP-2203-R2)

DRUG

NVP-2203-R

administration of active comparator

Trial Locations (1)

08779

H Plus Yangji Hospital, Seoul

Sponsors

Lead Sponsor

NVP Healthcare
All Listed Sponsors
lead

NVP Healthcare

INDUSTRY

NCT05725252 - To Evaluate the Safety and the Pharmacokinetics of NVP-2203 | Biotech Hunter | Biotech Hunter